New scan agent could spot tumors better in advanced cancers
NCT ID NCT07117214
First seen Jun 13, 2026 · Last updated Jun 21, 2026 · Updated 2 times
Summary
This early study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The goal is to see how well it highlights tumors on PET scans and to check its safety. It is a first-in-human trial, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGroningen, 9728, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-DWJ155 (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a new way to see tumors more clearly in scans, helping doctors better detect and monitor advanced breast and lung cancers.
What could go wrong
This is a very early phase 1 study with only 36 people, so it may not work as hoped or show clear benefits. The imaging agent is radioactive, which carries small risks like radiation exposure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.